UnitedHealth Group (NYSE:UNH), a leading diversified healthcare company with a substantial market capitalization of $469.7 ...

Insurer-pharmacy benefit manager (PBM) firms control most of the Medicare Part D market, steering patients to their ...

UnitedHealth Q4 earnings beat EPS estimates at $6.81 but missed revenue projections. Analysts highlight growth potential in ...

Healthcare fraud investigations accounted for more than half of the Department of Justice's settlements and judgments in 2024 ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Analyst Joanna Gajuk of Bank of America Securities maintained a Buy rating on UnitedHealth (UNH – Research Report), reducing the price target ...

The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for ...

Mizuho Securities analyst Ann Hynes has assigned their bullish stance on UNH stock, giving a Buy rating on January 15.Stay Ahead of the ...

This value-based world in which we find ourselves living presents a fascinating paradox. At the same time that it promises to ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story UnitedHealth CEO blames drug companies ...

UnitedHealth's CEO acknowledged discontent with the health care system, but quickly shifted the blame elsewhere.

UnitedHealth Group executives stressed the power of value-based care and Medicare Advantage to better people’s lives.